Valuation -- 5/10
DEO trades at a meaningful discount to spirits peers on both P/E (11.5x vs 15.7x peer avg)
and EV/EBITDA (9.7x vs 13.8x), with the stock near 52-week lows and RSI at 32 (near oversold).
The discount reflects real fundamental headwinds -- China revenue plunging 56%, tariff risk of
~$200M pre-mitigation, leverage at 3.4x above target, and GLP-1 sentiment overhang. New CEO
Dave Lewis (turnaround specialist) and the $625M Accelerate cost program are genuine catalysts,
but the strategic review is not yet complete and FY2027 earnings visibility remains low. At
$73.32, much of the bad news appears priced in, but the risk profile is complex, preventing
a higher score.
Weight: 15%
Forward P/E (FY+1)
11.5x
vs 15.7x peer avg
EV/EBITDA (LTM)
9.7x
vs ~13.8x peer avg
Dividend Yield
4.4%
$0.50 floor, 30-50% payout
Debt / EBITDA
3.4x
Target 2.5-3.0x
Peer valuation comparison
| Company | Fwd P/E | EV/EBITDA | Div Yield |
|---|---|---|---|
| Diageo (DEO) | 11.5x | ~9.7x | 4.4% |
| Brown-Forman (BF.B) | 17.5x | ~15x | ~2.1% |
| Constellation Brands (STZ) | 11.9x | ~11x | ~2.2% |
| Pernod Ricard (RI) | 11.6x | ~11x | ~3.5% |
| Remy Cointreau (RCO) | 21.6x | ~18x | ~1.8% |
| Peer Average | 15.7x | ~13.8x | ~2.4% |
| Key Takeaway | DEO trades at a 27% discount to peer avg P/E and 30% discount on EV/EBITDA. The valuation gap is wide enough to suggest much of the bad news is priced in. BF.B/Pernod merger talks (March 2026) could further compress peer multiples or highlight the discount. | ||
Peer multiples are approximate and based on consensus estimates. DEO data as of April 2026.
Data sourced from Daloopa and public filings.
Fundamental snapshot
| Metric | FY2024 | FY2025 | Trend | H1 FY2026 |
|---|---|---|---|---|
| Net Sales | $20.27B | $20.25B | Flat | $10.46B (-4.0%) |
| Adj. EBITDA | $7.04B | $6.65B | -5.6% | -- |
| Pre-Exceptional EPS (cents) | 179.6c | 164.2c | -8.6% | -- |
| Debt / EBITDA | 3.0x | 3.4x | Deteriorating | -- |
FY2026 guidance: organic net sales flat to slightly down; organic operating profit growth mid-single-digit including tariff impact.
Data sourced from Daloopa and public filings.
Key catalysts (2026-2027)
| # | Catalyst | Timeline | Magnitude | Probability |
|---|---|---|---|---|
| 1 | New CEO Dave Lewis -- turnaround specialist | Jan 2026+ | High | High |
| Former Tesco CEO who led a major turnaround. Already cutting costs, rebasing the dividend, and signaling willingness to divest non-core assets. Strategic update expected summer 2026. Identified customer service, operating framework redesign, and RTD expansion as immediate priorities. | ||||
| 2 | Accelerate Program -- $625M cost savings | FY2026-FY2028 | High | High |
| Three-year program targeting $625M in savings. ~50% expected to be delivered in FY2026 alone, front-loaded via supply chain, A&P efficiencies, and overhead reductions. Should support mid-single-digit organic operating profit growth despite top-line pressure. | ||||
| 3 | Potential China asset disposal | 2026 | Medium-High | Medium |
| Bloomberg reported (Jan 2026) Diageo is considering a sale of China assets (Shui Jing Fang). A disposal would remove a key earnings drag and simplify the equity story, though likely at a depressed valuation. | ||||
| 4 | US consumer recovery / rate cuts | H2 2026+ | Medium | Medium |
| ~40% of sales from North America. Any improvement in consumer confidence or interest rate environment would disproportionately benefit spirits volumes. US destocking cycle is largely complete; distributor inventories are normalized. | ||||
| 5 | Guinness momentum | Ongoing | Medium | High |
| 8th consecutive half of double-digit growth. Guinness 0.0 capacity being doubled. Premier League partnership driving global expansion. This brand alone is a meaningful growth engine. | ||||
| 6 | BF.B / Pernod merger as industry catalyst | 2026+ | Medium | Medium |
| Confirmed merger discussions (March 2026) could create a $30B spirits competitor. M&A activity in the sector could highlight premium portfolio and scale advantages, or put Diageo in play as an acquirer of divested brands. | ||||
Key risks (bear case)
| # | Risk | Severity | Probability | Detail |
|---|---|---|---|---|
| 1 | China exposure / Shui Jing Fang drag | HIGH | High | Chinese white spirits plunged 56% in H1 FY2026, dragging group organic net sales by ~2.5 pp. Anti-corruption campaigns have structurally reduced baijiu consumption -- this may be semi-permanent, not cyclical. |
| 2 | Tariff risk (~$200M pre-mitigation) | HIGH | Medium-High | US tariffs: 10% on UK/EU imports, 15% on European imports. ~$200M annualized pre-mitigation; Diageo expects to mitigate ~50%. USMCA exemption is critical -- ~46% of US net sales from Mexico/Canada imports (Don Julio, Casamigos, Crown Royal). |
| 3 | Balance sheet / elevated leverage | MED-HIGH | Medium | Debt/EBITDA rose to 3.4x in FY2025, above the 2.5-3.0x target range. Dividend rebased to $0.50 floor (from $1.03) frees ~$1.2B annually for debt reduction, but deleveraging takes time. |
| 4 | GLP-1 / alcohol consumption headwind | MEDIUM | Medium | Spirits show a 40% reduction in consumption among GLP-1 users. If 10% of US overweight population takes GLP-1s, alcohol demand could decline ~6%. Real but slow-moving: ~1-3% annual demand erosion, not a cliff. Largely reflected in sentiment/valuation. |
| 5 | USMCA exemption loss (tail risk) | SEVERE | Low-Medium | A return to 25% tariffs on Mexico/Canada would be devastating to the premium tequila and Canadian whisky portfolios. US Supreme Court ruling on tariff policy has increased legal uncertainty. |
| 6 | Regulatory / excise risk | LOW-MED | Low | Spirits face ongoing regulatory scrutiny globally (health warnings, advertising restrictions). WHO and national health bodies continue to advocate for higher excise taxes. Background risk, not acute. |
Bull and bear scenarios
Bull Case ($95-100, ~14-15x FY+1 EPS)
- New CEO Dave Lewis executes turnaround -- strategic review summer 2026 provides clarity
- Accelerate program delivers $625M savings, margins expand despite flat revenue
- China asset disposal removes key earnings drag and simplifies the equity story
- USMCA exemption holds, tariff mitigation better than expected
- Guinness momentum continues; brand alone is a meaningful growth engine
- Multiple re-rates toward peer average (15.7x) as turnaround gains credibility
Bear Case ($50-55, ~8-9x FY+1 EPS)
- China losses accelerate; write-down on Shui Jing Fang assets
- USMCA exemption revoked; 25% tariffs devastate tequila and Canadian whisky portfolios
- Leverage remains above target; debt markets reprice Diageo credit risk
- GLP-1 adoption accelerates; structural demand erosion exceeds 3% per annum
- Turnaround execution fails; Accelerate savings reinvested rather than dropped to margin
- LatAm/Africa weakness continues; premiumization stalls in key emerging markets
Score rationale
Score of 5/10 reflects a stock trading at a significant discount to peers, with real catalysts on the horizon, but a complex risk profile that prevents conviction.
Why not higher (6-7): The discount is partially justified by: (a) China exposure with Chinese white spirits down 56% and potential write-down risk, (b) material tariff risk of ~$200M pre-mitigation with USMCA exemption uncertainty being critical for ~46% of US net sales, (c) leverage at 3.4x above the 2.5-3.0x target range, and (d) the GLP-1 sentiment overhang with notable fund managers (Terry Smith) citing it as reason to exit. The strategic review under the new CEO is not yet complete, and FY2027 earnings visibility remains low. Revenue declined in H1 FY2026 (-4.0% reported) and guidance was lowered.
Why not lower (3-4): DEO trades at 11.5x forward P/E vs 15.7x peer average -- a 27% discount that suggests much of the bad news is priced in. The stock is near 52-week lows with RSI at 32 (near oversold). The new CEO Dave Lewis is a proven turnaround operator (Tesco). The Accelerate program targeting $625M in savings is front-loaded (~50% in FY2026). Guinness is delivering 8 consecutive halves of double-digit growth. The dividend yield of 4.4% provides a floor. BF.B/Pernod merger talks could catalyze sector re-rating.
Net assessment: At $73.32, DEO is an AVOID / Watchlist position. The valuation is undemanding and the catalyst list is real, but the risk profile is too complex for conviction. A score above 5 would require clarity on tariff exemptions for Mexico/Canada and evidence that Accelerate savings are translating to margin expansion.
Data sourced from Daloopa, company earnings transcripts, and public consensus estimates. Analysis as of April 2026.